На этой странице перечислены больницы направления «Пластическая и реконструктивная хирургия» (включая Mole Removal) в Дубай, ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.
Спросите нас о «Mole Removal» в Дубай, ОАЭ
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 3 аккредитованных больниц (Пластическая и реконструктивная хирургия) в Дубай, ОАЭ
Рекомендуем🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Больница занимает 1-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Kings College Hospital Dubai
Больница занимает 2-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Aster Hospital Dubai
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Пластическая и реконструктивная хирургия» указано среди её специализаций и она находится в Дубай, ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «mole removal» в Дубай, ОАЭ?
Выбор подходящей больницы для «mole removal» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Пластическая и реконструктивная хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Mole Removal»
Mole removal — clinically termed melanocytic nevus excision or shave excision — is a safe, highly effective dermatological and plastic surgery procedure used to eliminate benign, atypical, or cosmetically concerning skin lesions through techniques ranging from surgical excision with primary closure to laser ablation and radiofrequency shave removal. Procedural success rates exceed 95% for benign lesions, with recurrence rates below 2% when adequate margins are achieved, making it one of the most predictable outpatient procedures in plastic and dermatological surgery. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed clinics in Dubai and Abu Dhabi, offering world-class dermatopathological assessment, cosmetically superior closure techniques, and end-to-end care coordination at a fraction of Western costs. Hospital Stay: 0–1 days (outpatient for most cases; 1-day admission reserved for complex or multiple lesion excisions requiring general anaesthesia) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (simple shave or laser removal: 5–7 days; surgical excision with sutures: 10–14 days, once wound is epithelialized and there is no risk of haematoma at altitude) • Success Rate: 95–98% (complete excision with histologically clear margins; cosmetic satisfaction rates >90% in experienced plastic surgery centres)
Clinical Overview
A mole (melanocytic nevus) is a benign proliferation of melanocytes — the pigment-producing cells of the skin — that can be present at birth (congenital nevi) or develop throughout life in response to UV exposure, hormonal changes, or genetic predisposition. The vast majority of moles are clinically benign; however, a subset — particularly dysplastic (atypical) nevi, large congenital nevi, or lesions demonstrating the ABCDE criteria (Asymmetry, irregular Border, multiple Colours, Diameter >6 mm, Evolution) — carry an elevated risk of malignant transformation into melanoma, one of the most aggressive skin cancers. Dermatoscopic evaluation using polarised-light dermoscopy and, where indicated, reflectance confocal microscopy (RCM) allows clinicians to stratify lesions non-invasively before any incision is planned. From a physiological and histopathological standpoint, nevi are classified by their anatomical position within the skin: junctional nevi (melanocytes at the dermoepidermal junction), compound nevi (cells spanning both the junction and dermis), and intradermal nevi (entirely within the dermis, typically raised and dome-shaped). Spitz nevi and blue nevi are morphologically distinct subtypes that require particular expertise to differentiate from melanoma both clinically and histologically. Any excised specimen must undergo formal histopathological analysis — and in equivocal cases, immunohistochemical staining with markers such as HMB-45, Melan-A, and Ki-67 proliferation index — to confirm benign nature and complete excision. The current standard of care, as outlined by the British Association of Dermatologists and the American Academy of Dermatology, mandates dermoscopic triage, selective biopsy or complete excision with 2 mm clinical margins for benign lesions (and 5–10 mm margins for atypical/dysplastic nevi), followed by histopathological clearance. In aesthetically sensitive areas (face, neck, décolletage), the emphasis shifts to tension-free closure using deep dermal absorbable sutures (e.g., 4-0 Monocryl) and fine superficial sutures (5-0 or 6-0 Prolene) or tissue adhesive, to minimise scarring. Post-operative scar management with silicone gel sheets or intralesional triamcinolone is employed selectively for hypertrophic scar-prone individuals.
Who is a Candidate?
• ELIGIBLE CANDIDATES: • Patients with a mole exhibiting one or more ABCDE warning signs (Asymmetry, Border irregularity, Colour variegation, Diameter >6 mm, Evolution/change over time) • Individuals with dysplastic (Clark's) nevi confirmed on dermoscopy or prior biopsy, particularly those with a personal or family history of melanoma • Patients with congenital melanocytic nevi, especially giant congenital nevi (GCN >20 cm), which carry a lifetime melanoma transformation risk of 5–10% • Cosmetically bothersome raised, pigmented, or repeatedly traumatised moles causing physical discomfort (e.g., snagging on clothing, recurrent bleeding) • Patients with multiple atypical mole syndrome (Familial Atypical Multiple Mole and Melanoma syndrome, FAMMM) requiring surveillance excision • Patients who have had a prior incomplete excision (positive histological margins) requiring re-excision • REQUIRED PRE-PROCEDURAL DIAGNOSTICS: • Polarised-light dermoscopy (mandatory first-line triage tool; replaces need for blind excision in most cases) • Total-body photography (TBP) or mole mapping — recommended for patients with >50 nevi or personal/family history of melanoma • Reflectance confocal microscopy (RCM) or optical coherence tomography (OCT) — for lesions in cosmetically sensitive areas where excision would cause significant scarring and non-invasive rule-out of melanoma is desired • Punch biopsy with histopathology + immunohistochemistry (HMB-45, Melan-A, S-100, Ki-67) — for ambiguous lesions prior to planning definitive excision margins • Baseline blood tests (FBC, coagulation profile, fasting glucose) — required if general anaesthesia is planned • Pregnancy test (urine or serum beta-hCG) — for women of childbearing age if sedation or GA is being considered • RELATIVE CONTRAINDICATIONS: • Active anticoagulant therapy (warfarin, apixaban, rivaroxaban) without haematology-approved bridging protocol — increases intraoperative bleeding risk • Known keloid or hypertrophic scar tendency, especially for lesions on the chest, shoulders, or jaw — requires pre-counselling and modified technique • Uncontrolled diabetes mellitus (HbA1c >9%) — impairs wound healing; optimisation required before elective excision • Active skin infection or dermatitis in the operative field — procedure must be deferred until resolution • Immunosuppressed patients (post-transplant, on biological therapy) — require infectious disease clearance; higher wound complication risk • Lesions clinically suspicious for primary melanoma where sentinel lymph node biopsy (SLNB) planning is required — must be managed within a full melanoma MDT pathway, not as an isolated mole removal
Treatment Options & Approaches
STANDARD APPROACHES: 1. SURGICAL EXCISION WITH PRIMARY CLOSURE (Gold Standard for Atypical or Suspicious Nevi) The most oncologically sound method. Under local anaesthesia (1–2% lidocaine with 1:100,000 adrenaline), an elliptical excision is planned along Langer's lines of skin tension to ensure a cosmetically optimal scar orientation. Margins of 2 mm are used for clinically benign lesions; 5 mm for dysplastic nevi; and up to 1 cm for in situ melanoma (per NICE NG14 guidelines if malignancy is confirmed post-biopsy). Deep closure uses interrupted 3-0 or 4-0 absorbable Monocryl sutures to eliminate dead space and reduce wound tension; skin closure is with 5-0 or 6-0 Prolene or Ethilon, or alternatively Steri-Strip closure with tissue adhesive (Dermabond). Sutures are removed at 5–7 days (face) or 10–14 days (body). All specimens undergo formal histopathological review with margin assessment. 2. SHAVE EXCISION (For Raised, Benign, Intradermal Nevi) Using a DermaBlade or surgical scalpel angled at 15–30°, the raised portion of the mole is shaved flush with the surrounding skin surface. A shallow horizontal incision removes the bulk of the lesion without entering the deep dermis, minimising the risk of a linear scar. Haemostasis is achieved with aluminium chloride 20% solution or light electrocautery. This technique produces a flat, circular wound that heals by secondary intention over 2–4 weeks, typically with an excellent cosmetic result for dome-shaped intradermal nevi. Specimen histopathology is still mandatory to exclude unexpected dysplasia. 3. PUNCH EXCISION (For Small Nevi ≤6 mm) A circular punch biopsy tool (2–6 mm diameter) is used to core out small, well-defined moles in a single-step excise-and-biopsy procedure. The resulting circular defect is closed with 1–2 interrupted sutures or left to heal by secondary intention for very small defects. Punch excision offers speed, precision, and minimal surrounding tissue disturbance, making it ideal for facial nevi in areas such as the nasal tip or eyelid margin where tissue conservation is paramount. 4. CO2 LASER ABLATION AND Er:YAG LASER ABLATION (For Superficial, Benign Lesions in Cosmetically Sensitive Areas) Fractional CO2 laser (10,600 nm wavelength) or Er:YAG laser (2940 nm) vaporises melanocytic tissue layer-by-layer with minimal collateral thermal damage. CO2 laser offers simultaneous haemostasis; Er:YAG produces a cleaner ablation with faster healing. This approach is best reserved for clinically and dermoscopically confirmed benign flat or minimally raised moles where histopathological specimen retrieval is not the primary objective. It is not appropriate for any lesion with atypia, as no specimen is available for margin assessment. Downtime is 5–10 days of wound weeping and crusting. 5. RADIOFREQUENCY (RF) SHAVE REMOVAL High-frequency radiofrequency current (Surgitron or Ellman device, 3.8–4.0 MHz) allows bloodless, precise shave removal of raised nevi with simultaneous coagulation. The alternating current generates cellular heating causing tissue vaporisation without mechanical trauma. RF shave excision produces less thermal spread than electrocautery, resulting in superior cosmetic healing. Suitable for benign, raised nevi on the face, neck, and trunk; not indicated for suspicious or atypical lesions. 6. ADVANCED / RECONSTRUCTIVE APPROACHES (For Large or Facial Lesions) For large lesions (>2 cm) or nevi in cosmetically critical areas (nasal ala, lip, eyelid, ear), plastic surgeons employ local flap reconstruction (e.g., rhomboid flap, bilobed flap, Z-plasty, V-Y advancement flap) or full-thickness skin grafting (FTSG) to achieve primary closure without distorting adjacent anatomical structures. Giant congenital nevi may require staged tissue expander-assisted serial excision over multiple procedures. Intraoperatively, the CO2 laser may be used in combination with surgical excision to feather wound edges and improve final scar appearance. 7. MOHS MICROGRAPHIC SURGERY (For Lentigo Maligna / Melanoma In Situ on the Face) Where a mole excision reveals lentigo maligna or in situ melanoma in a cosmetically sensitive location, Mohs micrographic surgery — performed by a fellowship-trained Mohs surgeon — allows real-time, 100% margin assessment of the peripheral and deep margins using horizontal frozen sections. This tissue-sparing technique minimises the area of excision while ensuring complete histological clearance, and is endorsed by both NICE and the AAD for facial melanoma in situ.
Восстановление
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel) • Patient submits dermoscopic photographs or clinical images through GAF Healthcare's secure telemedicine portal for remote assessment by a board-certified dermatologist or plastic surgeon. • The treating physician provides a provisional classification (benign vs. atypical vs. suspicious) and recommends the appropriate excision technique and required pre-op investigations. • GAF Healthcare's medical coordinator prepares a detailed cost estimate, treatment plan, and coordinates e-Medical Visa documentation for India or UAE entry visa facilitation. • Pre-operative blood work (FBC, coagulation screen, HbA1c if diabetic) may be performed at the patient's home country and uploaded digitally to reduce time spent in the destination country. PHASE 2 — ARRIVAL & DAY-0 CONSULTATION • GAF Healthcare airport representative meets the patient and accompanies them to partner accommodation or directly to the hospital for same-day admission if scheduled. • In-person consultation with the operating surgeon: clinical examination, dermoscopy, photography, consent, and surgical plan finalisation. • For patients requiring mole mapping or RCM, this is performed on Day 0 or Day 1 at the dermatology department. • Anaesthetic review if IV sedation or general anaesthesia is planned (required for multiple lesion removal or anxious patients). PHASE 3 — THE PROCEDURE (Day 1 or 2) • The majority of mole removals are performed under local anaesthesia as a 15–45 minute outpatient procedure. • Local anaesthetic (1% lidocaine with 1:100,000 epinephrine) is infiltrated around the lesion; 10–15 minutes are allowed for vasoconstriction to reduce intraoperative bleeding. • Excision, shave, punch, or laser ablation is performed according to the pre-agreed technique. • Wound closure (sutures, tissue adhesive, or dressing) is completed; the specimen is dispatched to the histopathology laboratory. • Patient is discharged 1–2 hours post-procedure with wound care instructions, a 5-day course of topical antibiotic (mupirocin 2% or fusidic acid), and oral analgesics (paracetamol/ibuprofen — NSAIDs are typically adequate). PHASE 4 — EARLY RECOVERY (Days 2–7) • Day 2: First wound review by a nurse or surgeon; wound inspected for haematoma, seroma, or early infection signs; dressing changed. • Days 3–5: Patients may experience mild erythema, swelling, and tenderness. No strenuous exercise or swimming. Wound kept dry for the first 48 hours. • Day 5–7 (facial sutures): Suture removal performed by the clinical team; Steri-Strips applied for an additional 5–7 days to support wound edges. • Histopathology results typically available within 5–7 working days; GAF Healthcare facilitates secure digital delivery of the pathology report to the patient and their home country physician. PHASE 5 — PRE-DEPARTURE ASSESSMENT & FIT-TO-FLY CLEARANCE (Days 7–14) • Surgeon conducts a formal wound review and confirms epithelialisation is complete and there is no active infection, haematoma, or wound dehiscence. • Fit-to-fly letter is issued; patients are counselled on in-flight wound care (keep covered, avoid prolonged sun exposure during transit). • Recommended flight time post-procedure: 5–7 days for laser/shave procedures; 10–14 days for sutured excisions involving large defects or flap reconstructions. PHASE 6 — LONG-TERM FOLLOW-UP (Weeks 4–12 and Beyond) • Scar maturation occurs over 3–12 months. Silicone gel (e.g., Kelo-cote, Dermatix) applied twice daily from Week 2 onwards for 3–6 months significantly improves final scar quality. • Sun protection (SPF 50+) over the scar site is mandatory for 12 months to prevent post-inflammatory hyperpigmentation. • Histopathology-confirmed dysplastic nevi: 6-monthly total-body skin examination recommended; GAF Healthcare coordinates telemedicine follow-up with the treating dermatologist. • Recurrence (if it occurs) is typically identified within the first 12 months and managed with re-excision; GAF Healthcare's continuity-of-care protocol ensures patients can access their operative records from any country.
Возможные риски
Mole removal is among the lowest-risk outpatient procedures in dermatological surgery; however, informed consent requires discussion of the following procedure-specific considerations: SCARRING: All excisional techniques produce a scar. The final cosmetic outcome depends on lesion size and location, skin type (Fitzpatrick III–VI skin tones are at higher risk of post-inflammatory hyperpigmentation and hypertrophic scarring), surgical technique, and patient compliance with post-operative scar therapy. Keloid formation occurs in 5–15% of predisposed individuals (particularly on the chest, shoulders, and upper back) and may require intralesional triamcinolone injections, pulsed-dye laser (PDL), or silicone sheeting for management. INCOMPLETE EXCISION AND RECURRENCE: Shave excision and laser ablation carry a higher incomplete excision rate than elliptical surgical excision, as they do not routinely achieve deep histological margins. Recurrence (pseudomelanoma or true recurrence) is reported in 1–5% of shave-excised junctional or compound nevi and may mimic melanoma on subsequent dermoscopy, complicating re-assessment. INFECTION: Post-operative wound infection occurs in approximately 1–2% of cutaneous excisions. Risk is higher in diabetic patients, the immunosuppressed, and wounds in body fold areas. Managed with topical or oral antibiotics; rarely requires wound debridement. HAEMATOMA AND SEROMA: Small haematomas occur in <2% of cases; larger haematomas may require evacuation under aseptic conditions. Risk is elevated in patients on antiplatelet agents (aspirin, clopidogrel) who have not followed pre-operative medication guidance. NERVE INJURY: Excisions on the face (particularly near the marginal mandibular branch of the facial nerve, the supraorbital nerve, or the nasolabial fold) carry a small risk of temporary or, rarely, permanent sensory or motor nerve injury. This risk is minimised by surgeon knowledge of regional anatomy and use of loupe magnification. HISTOPATHOLOGY UPSTAGING: Approximately 1–3% of lesions excised as 'benign moles' are upstaged on histopathology to dysplastic nevi with positive margins, or, in rare cases, early melanoma. This is not a complication of treatment but an important reason why histopathological analysis of every excised specimen is non-negotiable. GAF Healthcare's protocol ensures all histopathology reports are reviewed by the operating surgeon and communicated to the patient within the treatment window before departure.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated, end-to-end support infrastructure designed to eliminate logistical friction for international patients travelling to India or the UAE for mole removal. VISA FACILITATION: For India: GAF Healthcare assists patients in applying for the e-Medical Visa (eMV), which allows a 60-day stay (extendable) and is approved for over 160 nationalities. Patients require a confirmed appointment letter from a recognised Indian hospital — which GAF Healthcare provides — along with standard documentation (passport, photograph, bank statement). Processing typically takes 3–5 working days. For the UAE (Dubai/Abu Dhabi): Citizens of over 90 countries receive visa-on-arrival or 30–90 day visa-free entry to the UAE, making it the most accessible destination for patients from Europe, Africa, the GCC, and South Asia. GAF Healthcare's UAE coordinator advises on country-specific entry requirements and coordinates any required medical entry approvals through the Dubai Health Authority (DHA) or Department of Health Abu Dhabi (DoH). AIRPORT TRANSFERS AND GROUND LOGISTICS: A dedicated GAF Healthcare representative meets the patient (and accompanying attendant) at the airport with a clearly identified name board. Climate-controlled, accessible vehicles are provided for all transfers between airport, accommodation, and hospital. For patients who are mobility-impaired or have multiple lesions requiring dressings, wheelchair-accessible transport is arranged in advance. DEDICATED PATIENT COORDINATOR AND TRANSLATION: Each patient is assigned a personal GAF Healthcare case coordinator who serves as the single point of contact throughout the journey — from pre-arrival documentation to post-discharge histopathology delivery. For patients who do not speak English, Hindi, or Arabic, GAF Healthcare provides certified medical interpreters or multilingual coordinators (Arabic, Russian, French, Swahili, and other languages available on request) who accompany the patient to all clinical consultations, procedure rooms, and follow-up appointments to ensure fully informed consent and clear communication. ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF Healthcare has negotiated preferential rates with partner hotels and serviced apartments within 5–15 minutes of all partner hospitals. Accommodation options range from budget-friendly guesthouses (for cost-sensitive patients) to five-star hotel suites adjacent to hospital campuses (particularly relevant in Dubai's Healthcare City and Apollo/Fortis hubs in India). Attendant accommodation is arranged within the same property to allow 24-hour patient support. Meals, laundry, and local SIM card procurement are coordinated by the GAF Healthcare ground team. POST-PROCEDURE CONTINUITY OF CARE: All operative notes, histopathology reports, wound photographs, and discharge summaries are compiled into a structured digital patient dossier and shared securely with the patient and their home country physician via GAF Healthcare's encrypted medical records portal. Telemedicine follow-up appointments with the treating surgeon are scheduled at Week 2 and Week 6 post-discharge, ensuring scar assessment and histopathological review are not lost to follow-up simply because the patient has returned home.
Частые вопросы о процедуре «Mole Removal»
What is the cost of mole removal in India versus the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after mole removal?
What is the success rate of mole removal, and what happens if a mole is found to be cancerous after excision?
Как GAF Healthcare помогает выбрать лучшую больницу для «mole removal» в Дубай, ОАЭ
Найдите лучшие больницы для «mole removal» в Дубай, ОАЭ
На этой странице представлено 3 больниц в Дубай, ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Mole Removal» в Дубай, ОАЭ
Сколько больниц направления «Пластическая и реконструктивная хирургия» представлено в Дубай, ОАЭ?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дубай, ОАЭ?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Mole Removal» в Дубай, ОАЭ.
Свяжитесь с нами, если заметите неточность на этой странице.